Выбор темы
Выбор стиля шрифта
Biogen новости
27/03
💡
МНЕНИЕ: Biogen рассчитывает на возврат к росту выручки благодаря продажам lecanemab и zuranolone -SUVE
30/03
💡
МНЕНИЕ: Biogen прогнозирует слабые продажи в 2022 г. - SUVE
03/02
🔗
Seeking Alpha: Biogen Inc. (BIIB) CEO Michel Vounatsos on Q4 2021 Results - Earnings Call Transcript
03/02
🔗
Schaeffers Research: Biogen Stock Hits 5-Year Low After Weak Forecast
03/02
🔗
Zacks Investment Research: Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates
03/02
🔗
Benzinga: Why Biogen Shares Are Sliding Today
03/02
🔗
Market Watch: Biogen's stock falls 3.7% on earnings miss, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter
03/02
🔗
Reuters: Biogen 2022 profit forecast misses estimates on Aduhelm woes
02/02
🔗
Zacks Investment Research: Drug/Biotech Stocks Earnings on Feb 3: BIIB, LLY & MRK
01/02
🔗
Benzinga: Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab
31/01
🔗
Zacks Investment Research: Is a Beat Likely for Biogen (BIIB) This Earnings Season?
28/01
🔗
Zacks Investment Research: Biogen (BIIB) to Sell Biosimilar JV Stake to Samsung Biologics
28/01
🔗
GuruFocus: Biogen Announces Cash Injection, Moves Forward With Alzheimer's Trials
22/01
🔗
The Motley Fool: Is Biogen a Buy?
22/01
🔗
Barrons: Biogen After the Alzheimer's Drug Debacle: Time to Sell the Parts?
17/01
🔗
The Motley Fool: Is Biogen a Buy After the Latest Aduhelm Disaster?
14/01
🔗
GuruFocus: Biogen Is More Likely to Be a Buyer Than Seller
14/01
💡
МНЕНИЕ: CMS не включил препарат Aduhelm от Biogen в программу Medicare - SUVE
13/01
🔗
Reuters: Biogen eyes potential acquisitions - Stat News
13/01
💡
МНЕНИЕ: В негативном сценарии (при прекращении продаж Aduhelm) котировки Biogen продолжат снижаться - Синара Инвестбанк
13/01
🔗
Market Watch: Guggenheim downgrades Biogen to neutral from buy after U.S. proposes limiting access to Alzheimer's drug
12/01
🔗
Pulse2: Biogen Stock (BIIB): Why The Price Dropped Today
12/01
🔗
Zacks Investment Research: Biogen (BIIB) Down on Medicare Draft Ruling for Alzheimer's Drugs
12/01
🔗
The Motley Fool: Why Biogen Stock Is Sinking Today
12/01
🔗
Market Watch: Biogen's stock tumbles after the U.S. proposes restricting access to its Alzheimer's disease drug
12/01
🔗
Business Insider: Biogen sinks 10% after Medicare limits coverage of new Alzheimer's drug Aduhelm
12/01
🔗
The Motley Fool: Will This Stock's Pain Be Medicare's Gain?
12/01
🔗
Reuters: Biogen slumps after Medicare's restrictive decision on Alzheimer's drug
12/01
🔗
CNBC Television: Medicare will cover Biogen's $28K Alzheimer's drug, only in trials
12/01
🔗
Market Watch: Biogen stock falls more than 6% after Medicare plans coverage limits for pricy Alzheimer's drug
10/01
🔗
Seeking Alpha: Biogen Inc. (BIIB) CEO Michel Vounatsos on JPMorgan 40th Annual Healthcare Conference (Transcript)
08/01
🔗
Barrons: Biogen's Alzheimer's Drug Has Another Shot at Success
07/01
🔗
Barrons: Biogen's Alzheimer's Drug Has Another Shot at Success
07/01
🔗
The Motley Fool: Better Buy: Vertex Pharmaceuticals vs. Biogen
05/01
🔗
Zacks Investment Research: Why Biogen Inc. (BIIB) is Poised to Beat Earnings Estimates Again
05/01
🔗
Zacks Investment Research: Biogen (BIIB) Opts for In-Licensing SMA Therapy From Ionis
05/01
🔗
GuruFocus: These Emerging Biotechs Could Beat Alzheimer's Disease
04/01
🔗
CNBC: What's The Controversy Behind Biogen's Alzheimer's Drug
03/01
🔗
Benzinga: Medicare Trying To Determine Coverage Of Biogen's Expensive Alzheimer's Drug: NYT
01/01
🔗
Seeking Alpha: Anti-Amyloid Drugs: The Failure Of Success
30/12
🔗
Zacks Investment Research: Biogen (BIIB) Surges Amid Rumors of Acquisition by Samsung
30/12
🔗
Business Insider: Biogen tanks 8% after Samsung denies report it was in talks to buy the drugmaker
30/12
🔗
Yahoo Finance: Citi raises price targets for Ford, GM & Tesla, Biogen stock falls after Samsung rebuts acquisition
30/12
🔗
Market Watch: Biogen shares slump after Samsung Biologics denial of buyout report
30/12
🔗
TechXplore: Samsung in talks to buy Biogen for $42 bn: report
30/12
🔗
The Motley Fool: Why Biogen Stock Was a Winner on Wednesday
30/12
🔗
Proactive Investors: US stocks end mixed amid inflation, Omicron concerns
24/12
🔗
Zacks Investment Research: Biogen's (BIIB) Alzheimer's Disease Drug Gets FDA Fast Track Tag
24/12
🔗
Seeking Alpha: Biogen: All About Aduhelm Again In 2022, But Expecting Upside
23/12
🔗
Zacks Investment Research: Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know
22/12
🔗
Seeking Alpha: The Bottom Fishing Club: Biogen
22/12
🔗
Market Watch: Japan regulator to continue deliberations on Biogen and Eisai's Alzheimer's drug
21/12
🔗
Zacks Investment Research: Biogen (BIIB) to Cut Alzheimer's Drug Aduhelm Price by 50%
20/12
🔗
Market Watch: Biogen's decision to halve price of Alzheimer's drug is ‘a day late and a dollar short,' says Raymond James
20/12
🔗
Benzinga: After Much Criticism, Biogen Slashes Aduhelm Price In Half
20/12
🔗
Market Watch: Biogen to lower price of Alzheimer's drug aduhlem by 50% starting Jan. 1 to about $28,200 a year
18/12
🔗
Seeking Alpha: Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market
17/12
🔗
Zacks Investment Research: Biogen (BIIB) to Begin Aduhelm Confirmatory Study in 2022
17/12
🔗
Barrons: Biogen Says EU Regulator Takes 'Negative Opinion' on Its Alzheimer's Drug
17/12
🔗
Pulse2: Biogen Stock (BIIB): Why The Price Fell Today
17/12
🔗
The Motley Fool: Biogen's Alzheimer's Drug To Enter New Trial Stage Next Year
16/12
🔗
Benzinga: Biogen Outlines Aduhelm's Confirmatory Trial Plans, Data Expected In 2026
16/12
🔗
Market Watch: Biogen plans to start Phase 4 confirmatory study for Alzheimer's drug next year
08/12
🔗
CNBC Television: Are Biogen or Zimmer Biomet recommended buys? #AskHalftime
07/12
🔗
Seeking Alpha: Biogen's Stock Price Currently Matches Intrinsic Value - Buy Their Pipeline For Nothing
03/12
🔗
The Motley Fool: Should You Blame Biogen for Medicare Part B Premium Hikes?
03/12
🔗
Zacks Investment Research: Sage (SAGE), Biogen (BIIB) Report Data on Depression Drug
01/12
🔗
Invezz: Is it too late to sell Biogen stock after losing an appeal on its multiple sclerosis drug?
30/11
🔗
Benzinga: Biogen Loses Bid To Revive Tecfidera Drug Patent: Bloomberg
22/10
МНЕНИЕ: Biogen отчиталась лучше ожиданий и повысила прогноз на 2021 г.
09/09
📉
Акции Biogen рухнули на 8% из-за трудностей с лекарствами
25/06
Сектор здравоохранения "оздоровился" - Финам
07/06
📈
Акции Biogen взлетели на 60% на одобрении лекарства от Альцгеймера
Загрузить еще